Dan Lu is a distinguished leader and scientific expert in antibody drug research and development, with extensive industrial experience in biotechnology. They possess strong hands-on skills and a deep understanding of antibody discovery and biologics development, having led efforts from early R&D to IND for various therapeutic antibodies. Dan has contributed to the commercialization of notable drugs like Cetuximab, Ramucirumab, and Necitumumab, and holds more than 22 papers and 6 patents in the protein/antibody research field. Their previous roles include serving as Distinguished Scientist and Head of Antibody Discovery at Kadmon, a Sanofi Company, and as a Senior Scientist at ImClone Systems. Dan holds an educational background from the CUNY New York City College of Technology.
This person is not in the org chart
This person is not in any teams
This person is not in any offices